Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 5, 2014

View Archived Issues

Novartis reflects on key developments of fourth quarter 2013

Preclinical validation of intranasal delivery of stem cell-based cancer therapeutics

Development of a novel genetic vaccine against viral-mediated respiratory disease

Pfizer reports topline results from PALOMA-1 trial in advanced breast cancer

Edison Pharmaceuticals' EPI-743 receives FDA orphan drug status for Friedreich's ataxia

NeuroPore Therapies begins preclinical development of lead treatment candidate

Cellceutix files trial protocol with FDA for novel antibiotic brilacidin

GSK-2140944 shows efficacy in in vitro and in vivo models of infection

Mitsubishi Tanabe Pharma profiles progress of third quarter of fiscal 2013

Phase II study demonstrates IRX-4204 to be well tolerated in patients with metastatic CRPC

Bayer and German Cancer Research Center form alliance against cancer

Bionor Pharma identifies potential biomarker for Vacc-4x treatment in HIV infection

FDA issues complete response letter for VersaFilm for acute migraine

Rockwell Medical completes phase III program for iron replacement drug Triferic

Euclises Pharmaceuticals presents novel NO-releasing coxibs

Nimbus Discovery patents new IRAK-4 inhibitors

Amarantus BioScience reports phase IIa data for eltoprazine in adult ADHD

Janssen R&D Ireland presents novel TLR7 agonists

Scientists at Bayer Schering Pharma divulge new AKR1C3 inhibitors

Valeant Pharmaceuticals to acquire PreCision Dermatology

Forest Laboratories' acquisition of Aptalis complete

bioTheranostics launches suite of genomic-based tests

Chiesi Farmaceutici acquires Cornerstone Therapeutics

Hawaii Biotech receives NIH grant for anthrax anti-toxin drugs

Sosei and FUJIFILM Pharma sign distribution agreement for Loramyc in Japan

Advanced Cancer Therapeutics launches phase I trial of ACT-PFK-158

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...